ArticleCytoJournal2026
Mapping the function of EF-hand domain-containing protein 2 and determining its clinical relevance in non-small-cell lung cancer through single-cell transcriptomics.
Article in CytoJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to explore the cellular composition and transcriptional variability within the tumor microenvironment (TME) of non-small-cell lung cancer (NSCLC) using single-cell RNA sequencing (scRNAseq) and to assess the role of EF-hand domain-containing protein 2 (EFHD2) in tumor progression and its involvement in relevant signaling pathways. Material and Methods: We analyzed scRNA-seq datasets to map the cellular and transcriptional landscape of NSCLC tumors. Immunohistochemistry (IHC) was employed to validate the expression of EFHD2 and assess immune cell infiltration in clinical samples. To further investigate the functional effect of EFHD2, we performed Western blot and quantitative real-time polymerase chain reaction analyses as well as cell proliferation, migration, invasion, and apoptosis assays. We also explored the janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling pathway as a potential underlying mechanism. Results: The scRNA-seq analysis revealed that epithelial cells were the predominant population within the TME, alongside endothelial cells, fibroblasts, macrophages, and a small proportion of stem cells. EFHD2 expression exhibited considerable variability, with higher levels associated with clusters enriched in transcriptionally active and immunomodulatory pathways. The IHC results demonstrated elevated EFHD2 expression and immune cell infiltration in tumor tissues compared with adjacent non-tumor tissues. Conclusion: EFHD2 expression in the NSCLC TME correlates with immune cell infiltration and may play a significant role in tumor progression and immune modulation. The JAK-STAT signaling pathway may be a potential mechanism underlying the effect of EFHD2. This work provides a new avenue for targeted therapy in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.